-
Mashup Score: 2Pashtoon Kasi: All about efficiency - OncoDaily - 24 day(s) ago
Pashtoon Kasi: All about efficiency / cancer, City of Hope, FDA, nivolumab, OncoDaily, Oncology, Pashtoon Kasi
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Talk to your doctor STAT if you have any of these symptoms.
Source: parade.comCategories: General Medicine News, Hem/OncsTweet-
Honored to share insights on a critical topic with @ParadeMagazine📘. 📢 Rising rates of #ColorectalCancer in young adults are alarming. Know the signs & don’t delay screenings if eligible. Early detection saves lives. 🩺 ✍️@ohheyjesssager Read more: https://t.co/3D8COqHVxV
-
-
Mashup Score: 15Randy Moss' Rare GI Cancer: Here's What to Know - 1 month(s) ago
Hall of Fame football player recently revealed his cholangiocarcinoma diagnosis
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet-
“Randy Moss' Rare GI Cancer: Here's What to Know” Had the opportunity to talk about cholangiocarcinoma with @medpagetoday. With increasing options, cholangiocarcinoma is becoming a poster child for precision medicine. @cityofhope @curecc https://t.co/Ijff68oD1p
-
-
Mashup Score: 14City of Hope Buys 52 Acres in Orange County for $89M - 1 month(s) ago
The cancer treatment network paid $108M in 2020 for 11 acres and a 190K-SF building there to build its Lennar Foundation Cancer Center.
Source: commercialobserver.comCategories: General Medicine News, Hem/OncsTweet-
🗞️Our cancer center continues to grow exponentially📈. The impact it’s having in Orange County & nationwide is palpable. More options for our patients.🙌🏽 @cityofhopeoc @cityofhope “City of Hope Buys 52 Acres in Orange County for $89M.” @commobserver 📰 https://t.co/CPyigvGR0P
-
-
Mashup Score: 2Pashtoon Kasi: Thrilled to be at the CureCRC summit - OncoDaily - 1 month(s) ago
Pashtoon Kasi: Thrilled to be at the CureCRC summit / cancer, Colorectal Cancer Alliance summit, CureCRC summit, OncoDaily, Oncology, Pashtoon Kasi
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Thrilled to be at the CureCRC summit - @pashtoonkasi @CCAlliance https://t.co/tdyTJbiHJM #Cancer #ColorectalCancer #Onco…
-
-
Mashup Score: 2
AbstractPurpose:. To compare the efficacy and safety of high-dose vitamin C plus FOLFOX ± bevacizumab versus FOLFOX ± bevacizumab as first-line treatment in patients with metastatic colorectal cancer (mCRC).Patients and Methods:. Between 2017 and 2019, histologically confirmed patients with mCRC (n = 442) with normal glucose-6-phosphate dehydrogenase status and no prior treatment for metastatic disease were randomized (1:1) into a control (FOLFOX ± bevacizumab) and an experimental [high-dose vitamin C (1.5 g/kg/d, intravenously for 3 hours from D1 to D3) plus FOLFOX ± bevacizumab] group. Randomization was based on the primary tumor location and bevacizumab prescription.Results:. The progression-free survival (PFS) of the experimental group was not superior to the control group [median PFS, 8.6 vs. 8.3 months; HR, 0.86; 95% confidence interval (CI), 0.70–1.05; P = 0.1]. The objective response rate (ORR) and overall survival (OS) of the experimental and control groups were similar (ORR,
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
@Aiims1742 @OncoAlert @PanCAN This is the first randomized trial I believe showing a tangible benefit in #KRAS-mutant cancers as a primary endpoint. 👇🏽The VITALITY🍊study is worthy of mention since in that study too, there was a signal in the subset with RAS-mutant #ColorectalCancer. https://t.co/e2Sd8zv8Qu https://t.co/Epa9WUTOgS
-
-
Mashup Score: 4
Our findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
@Aiims1742 @OncoAlert @PanCAN Survival of patients on the recent NAPOLI-3 trial was 9.2 months for the Gem/Nab-Paxlitaxel arm. Median OS for the triplet was 11.1 months. So a median OS of 16 months in a randomized trial for someone with #PancreasCancer on GA is clinically meaningful. https://t.co/pcY0W2NiqZ https://t.co/r4FahT4z2S
-
-
Mashup Score: 3
PURPOSETo investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @alfdestefano: Just published the IMPROVE Trial | Journal of Clinical Oncology https://t.co/NELkZA0mTu @pashtoonkasi I remember when you…
-
-
Mashup Score: 3
PURPOSETo investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @alfdestefano: Just published the IMPROVE Trial | Journal of Clinical Oncology https://t.co/NELkZA0mTu @pashtoonkasi I remember when you…
-
-
Mashup Score: 3
PURPOSETo investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @alfdestefano: Just published the IMPROVE Trial | Journal of Clinical Oncology https://t.co/NELkZA0mTu @pashtoonkasi I remember when you…
-
RT @oncodaily: Subcutaneous nivolumab now @US_FDA approved across indications - @pashtoonkasi https://t.co/ibB3bDghuP #Cancer #FDAApprov…